http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#Head http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#provenance http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#pubinfo http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion http://purl.obolibrary.org/obo/DOID_14330 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_14330 http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00413 http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association http://www.w3.org/2000/01/rdf-schema#label mirapex r pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson s disease the effectiveness of mirapex tablets was demonstrated in randomized controlled trials in patients with early parkinson s disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa see clinical studies mirapex tablets are indicated for the treatment of moderate to severe primary restless legs syndrome rls key diagnostic criteria for rls are an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations symptoms begin or worsen during periods of rest or inactivity such as lying or sitting symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues and symptoms are worse or occur only in the evening or night difficulty falling asleep may frequently be associated with symptoms of rls http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00413 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#provenance http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#pubinfo http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig http://purl.org/nanopub/x/hasSignature GN4KrmT1rluDJrEveV8UvSW1Wo3+mYqwoTWmdrxfwDCBLN2Vw0EkGCeeVRzFKEVXr5h4/b1gQuprBYlkLMvX780tW02Gl4tlfIM1nse2Bd0FHpL1V5kC/e9il6Vhib74P1x5nBne8zYtv+7n+FNV6hBpzCeKqX5ADKBfiZgThN8= http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://purl.org/dc/terms/created 2021-06-30T09:10:36.868+02:00 http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA1xuPfR0V8bwo2wTzpY2TjGhtDuo1ib8nLy0zs_MwnYw https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs